THERAPEUTIC AND DIAGNOSTIC GUIDELINES

706 Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective
Lee LX, Li SC

OPINION REVIEW

721 Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations
Pham PV, Vu NB

REVIEW

731 Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection
Mallis P, Michalopoulos E, Chatzistamatiou T, Stavropoulos-Giokas C

752 Practical choice for robust and efficient differentiation of human pluripotent stem cells
Fang M, Liu LP, Zhou H, Li YM, Zheng YW

761 Human embryonic stem cells as an in vitro model for studying developmental origins of type 2 diabetes
Chen ACH, Lee KF, Yeung WSB, Lee YL

776 Autophagy in fate determination of mesenchymal stem cells and bone remodeling
Chen XD, Tan JL, Feng Y, Huang LJ, Zhang M, Cheng B

787 Stem cell therapy for Alzheimer's disease
Liu XY, Yang LP, Zhao L

803 Exosomes derived from stem cells as an emerging therapeutic strategy for intervertebral disc degeneration
Hu ZL, Li HY, Chang X, Li YY, Liu CH, Gao XX, Zhai Y, Chen YX, Li CQ

814 Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine
Ma ZJ, Yang JJ, Lu YB, Liu ZY, Wang XX

ORIGINAL ARTICLE

Basic Study

841 Assessment of tobacco heating system 2.4 on osteogenic differentiation of mesenchymal stem cells and primary human osteoblasts compared to conventional cigarettes
Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure
Bahrehbar K, Rezaazadeh Valojerdi M, Esfandiari F, Fathi R, Hassani SN, Baharvand H

Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review
Wang JH, Liu XL, Sun JM, Yang JH, Xu DH, Yan SS
ABOUT COVER

Editorial Board member of *World Journal of Stem Cells*, Dr. Perez-Campo is currently an Associate Professor in the Department of Molecular Biology at the University of Cantabria (Spain). She obtained her degree in Biological Sciences from the University of Salamanca (Spain), where she then went on to complete her PhD in 1999. Dr. Perez-Campo undertook her postdoctoral research at the Paterson Institute for Cancer Research (United Kingdom; currently known as Cancer Research UK Manchester Institute) under the supervision of Prof. Lacaud, where she remained for more than 10 years working in the field of stem cell biology. Upon returning to Spain, she joined the University of Cantabria and focused her research efforts on the molecular mechanisms that control mesenchymal stem cell (MSC) differentiation towards the osteoblastic and adipogenic lineages, and how those mechanisms are altered in osteoporosis. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of *World Journal of Stem Cells* (*WJSC, World J Stem Cells*) is to provide scholars and readers from various fields of stem cells with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJSC* publishes articles reporting research results obtained in the field of stem cell biology and regenerative medicine, related to the wide range of stem cells including embryonic stem cells, germline stem cells, tissue-specific stem cells, adult stem cells, mesenchymal stromal cells, induced pluripotent stem cells, embryonal carcinoma stem cells, hemangioblasts, lymphoid progenitor cells, etc.

INDEXING/ABSTRACTING

The *WJSC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Biological Abstracts, BIOSIS Previews, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJSC* as 3.231; IF without journal self cites: 3.128; Ranking: 18 among 29 journals in cell and tissue engineering; Quartile category: Q3; Ranking: 113 among 195 journals in cell biology; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yan-Xia Xing; Production Department Director: Yun-Xiaojian Wu; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

*World Journal of Stem Cells*

ISSN

ISSN 1948-0210 (online)

LAUNCH DATE

December 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Carlo Ventura

EDITORIAL BOARD MEMBERS


PUBLICATION DATE

August 26, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS

https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS

https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT

https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS

https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION

https://www.f6publishing.com
Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review

Jing-Hua Wang, Xiao-Ling Liu, Jian-Mei Sun, Jing-Han Yang, Dong-Hua Xu, Shu-Shan Yan

Abstract

BACKGROUND
Mesenchymal stem cells (MSCs) have been reported to possess immune regulatory effects in innate and adaptive immune reactions. MSCs can mediate intercellular communications by releasing extracellular vesicles (EVs), which deliver functional molecules to targeted cells. MSC derived EVs (MSC-EVs) confer altering effects on many immune cells, including T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages. A large number of studies have suggested that MSC-EVs participate in regulating autoimmunity related diseases. This characteristic of MSC-EVs makes them be potential biomarkers for the diagnosis and treatment of autoimmunity related diseases.

AIM
To verify the potential of MSC-EVs for molecular targeted therapy of autoimmunity related diseases.

METHODS
Literature search was conducted in PubMed to retrieve the articles published between 2010 and 2020 in the English language. The keywords, such as “MSCs,”
“EVs,” “exosome,” “autoimmunity,” “tumor immunity,” and “transplantation immunity,” and Boolean operator “AND” and “NOT” coalesced admirably to be used for searching studies on the specific molecular mechanisms of MSC-EVs in many immune cell types and many autoimmunity related diseases. Studies that did not investigate the molecular mechanisms of MSC-EVs in the occurrence and development of autoimmune diseases were excluded.

RESULTS
A total of 96 articles were chosen for final reference lists. After analyzing those publications, we found that it had been well documented that MSC-EVs have the ability to induce multiple immune cells, like T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages, to regulate immune responses in innate immunity and adaptive immunity. Many validated EVs-delivered molecules have been identified as key biomarkers, such as proteins, lipids, and nucleotides. Some EVs-encapsulated functional molecules can serve as promising therapeutic targets particularly for autoimmune disease.

CONCLUSION
MSC-EVs play an equally important part in the differentiation, activation, and proliferation of immune cells, and they may become potential biomarkers for diagnosis and treatment of autoimmunity related diseases.

Key words: Mesenchymal stem cells; Extracellular vesicles; Exosome; Autoimmunity; Tumor immunity; Transplantation immunity

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Mesenchymal stem cells (MSCs) have been reported to possess immunomodulatory effects on autoimmune responses. MSCs can mediate intercellular communications by releasing extracellular vesicles (EVs), which deliver functional molecules to targeted cells. MSC derived EVs (MSC-EVs) exert immunomodulatory effects on many immune cells. A large number of studies have suggested that MSC-EVs and the encapsulated bioactive molecules are potential targets for autoimmune disease, cancer, and other diseases. However, there is still a long way for investigating the molecular mechanism of MSC-EVs in autoimmunity. This review will focus on the immunomodulatory function and underlying mechanism of MSC-EVs in autoimmunity related diseases.

INTRODUCTION
Mesenchymal stem cells (MSCs) are a group of common multipotent progenitor cells, which can be found in bone marrow[1-3], synovium[4-6], umbilical cord[7,8], and adipose tissue[9]. They are characterized by a multilineage differentiation potential and paracrine function[10]. There is growing evidence that MSCs exert immunomodulatory effects through their paracrine function[11,12], in which multiple small molecules, including extracellular vesicles (EVs), cytokines, chemokines, growth factors, and interleukin(IL), are secreted to the extracellular microenvironment in animal models[13]. Recently, numerous studies demonstrated that MSCs can be used in clinical therapy for immunomodulation and regenerative medicine in vivo and in vitro[14-18]. Despite great improvements in the MSC therapeutic strategies for autoimmune diseases, treatment failures are still common and there is no doubt that it is imperative to carry out more studies to investigate the specific molecular mechanisms. EVs are key components of the paracrine process that play a vital role in intercellular communication by transmitting biological molecules in pathological and physiological
EVs are usually released during the stage of cell apoptosis. EVs participate in the intercellular communication by delivering numerous proteins and nucleotides with biological activity, and nucleotides include microRNAs (miRNAs), long non-coding RNAs (lncRNAs), mRNA, and even extra-chromosomal DNA[20-23]. They play vital roles in regulating inflammation, immune response, vascular reactivity, and tissue repair[24,25]. During the past few decades, MSC derived EVs (MSC-EVs) have been implicated in regulating inflammation and autoimmune[26]. It has been well established that EVs are involved in regulating autoimmune disorders by delivering a large number of bioactive molecules, including cytokines, enzymes, transcription factors, cytokines receptor antagonists, miRNAs, lncRNAs, and circRNAs[26-28]. MSCs, as a specific group of cells, are multipotent stem cells characterized by immunomodulatory and self-renewal properties[29,30]. Cosenza et al[31] have reported the important pathogenic or therapeutic role of MSC-EVs in rheumatic diseases. Therefore, we proposed that MSC-EVs can become potential biotargets for the development of novel molecular targeted drugs in autoimmune related diseases based on the above conclusions. This systematic review will provide in-depth knowledge of biogenesis and functional roles of MSC-EVs, especially exosomes, in autoimmunity.

MATERIALS AND METHODS

Literature search
The key words “MSCs,” “EVs,” “exosome,” “autoimmunity,” “tumor immunity,” and “transplantation immunity” were used to retrieve relevant articles published in English from 2010 to 2020 in PubMed database. Besides, Boolean operator “AND” and “NOT” were combined admirably with those keywords to search the related articles. Reference lists from those articles were reviewed to exclude irrelevant articles. Manuscripts available were reviewed and recognized by using document management tool. All available information was obtained by skimming the abstracts of searched articles. Data were analyzed using descriptive statistics. All repetitive documents were excluded, and the remainder needed to be restored for reading. Nevertheless, full text retrieval was performed due to many documents with unavailable abstract.

Statistical analysis
This article was a systematic review and no statistical method was used in this article.

RESULTS
Initially, we retrieved 198 records for this review. Then, repetitive and irrelevant documents were excluded, and we retained ultimately 96 high-quality papers with innovative viewpoints for reference lists. The screening process of those documents is showed in Figure 2.

EVs can regulate many immune and inflammatory responses by mediating intercellular communication. Moreover, MSC-EVs have been well documented to
induce multiple immune cells to mediate immune responses in innate immunity and adaptive immunity, namely, they modulate the differentiation, activation, and proliferation of immune cells, like T lymphocytes, B lymphocytes, natural killer cells (NKs), dendritic cells (DCs), and macrophages in the autoimmune system (Figure 3)\[38-41]\.

There is growing evidence that MSC-EVs serving as a type of signal molecules play major biological roles in the initiation, maintenance, and progression of multiple autoimmune related diseases, such as autoimmune diseases, cancer, and graft-versus-host disease. The features of MSC-EVs immunomodulation and their therapeutic potential in autoimmune related diseases are summarized in Tables 1 and 2.

**DISCUSSION**

**MSC-EVs and T lymphocytes**

T lymphocytes are important immune cells in adaptive immunity and play a significant role in the occurrence and development of many autoimmune and inflammatory diseases. MSC derived exosomes and microparticles down-regulate T cell proliferation, and CD4\(^+\) and CD8\(^+\) T cell subsets decrease significantly in quantity\[7\]. Adipose mesenchymal stem cell (AMSC) derived exosomes depress the
Table 1 Immune modulation of extracellular vesicles in autoimmune related diseases

<table>
<thead>
<tr>
<th>Disease</th>
<th>EVs</th>
<th>Expression</th>
<th>MSC-EVs source/Target molecules</th>
<th>Target immune cells</th>
<th>Pathway(s) involved</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>MSC derived exosomal miR-150-5p</td>
<td>Down</td>
<td>Bone marrow derived MSC-EVs/MMP 14 and VEGF</td>
<td>Macrophages</td>
<td>TGF-β pathway</td>
<td>Chen et al[80]</td>
</tr>
<tr>
<td></td>
<td>Exosome-encapsulated miR-548a-3p</td>
<td>Down</td>
<td>TLR4</td>
<td>Macrophages</td>
<td>Mir-548a-3p/TLR4/NF-κB axis</td>
<td>Wang et al[82]</td>
</tr>
<tr>
<td></td>
<td>Exosome-encapsulated miR-6089</td>
<td>Down</td>
<td>TLR4</td>
<td>Macrophages</td>
<td>TLR4/NF-κB signaling pathway</td>
<td>Xu et al[82]</td>
</tr>
<tr>
<td></td>
<td>Exosome-derived lncRNA Hotair</td>
<td>Up</td>
<td>MMP-2 and MMP-13</td>
<td>Macrophages</td>
<td>-</td>
<td>Song et al[83]</td>
</tr>
<tr>
<td></td>
<td>Exosomal miR-17</td>
<td>Up</td>
<td>TGFBR II</td>
<td>T cells</td>
<td>-</td>
<td>Wang et al[84]</td>
</tr>
<tr>
<td></td>
<td>MicroRNA-155</td>
<td>Up</td>
<td>SHIP-1</td>
<td>Macrophages</td>
<td>-</td>
<td>Kurowska-Stolarska et al[85]</td>
</tr>
<tr>
<td></td>
<td>MicroRNA-146</td>
<td>Up</td>
<td>-</td>
<td>Macrophages, T cells, B cells</td>
<td>-</td>
<td>Nakasa et al[86]</td>
</tr>
<tr>
<td>SLE</td>
<td>Exosomal miR-23a</td>
<td>Up</td>
<td>Podocyte proteins, actin family members, and intermediate filaments</td>
<td>Podocytes</td>
<td>-</td>
<td>Ichii et al[87]</td>
</tr>
<tr>
<td></td>
<td>Exosomal miRNA-146a</td>
<td>Up</td>
<td>-</td>
<td>-</td>
<td>Interferon-γ pathway</td>
<td>Perez-Hernandez et al[88]</td>
</tr>
<tr>
<td>pSS</td>
<td>EV derived LCN2</td>
<td>Up</td>
<td>TNF-α</td>
<td>B cells</td>
<td>TNF-α signaling</td>
<td>Aqrawi et al[89]</td>
</tr>
<tr>
<td></td>
<td>EV derived APMAP</td>
<td>Up</td>
<td>TNF-α</td>
<td>B cells</td>
<td>TNF-α signaling</td>
<td>Aqrawi et al[89]</td>
</tr>
<tr>
<td></td>
<td>EV derived CPNE1</td>
<td>Up</td>
<td>TNF-α</td>
<td>B cells</td>
<td>TNF-α signaling</td>
<td>Aqrawi et al[89]</td>
</tr>
<tr>
<td>IBD</td>
<td>MSC-EVs</td>
<td>Up</td>
<td>Bone marrow derived MSC-EVs</td>
<td>Macrophages</td>
<td>JAK1/STAT1/STAT6 signaling pathway</td>
<td>Cao et al[90]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Exosomal PD-L1</td>
<td>Down</td>
<td>PD-1</td>
<td>T cells</td>
<td>PD-L1/ PD-1 pathway</td>
<td>Yang et al[91]</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>EV derived miR-103a</td>
<td>Up</td>
<td>Lung cancer cell derived EVs/PTEN</td>
<td>Macrophages</td>
<td>PI3K/AKT and STAT3 axis</td>
<td>Hsu et al[92]</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Exosomal miR-301a-3p</td>
<td>Up</td>
<td>PTEN</td>
<td>Macrophages</td>
<td>PI3Kγ signaling pathway</td>
<td>Wang et al[93]</td>
</tr>
<tr>
<td>GVHD</td>
<td>MSC-EVs</td>
<td>Up</td>
<td>T cell derived EVs</td>
<td>-</td>
<td>-</td>
<td>Park et al[94]</td>
</tr>
</tbody>
</table>

RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; pSS: Primary Sjögren’s syndrome; IBD: Inflammatory bowel diseases; GVHD: Graft-versus-host disease; MSC: mesenchymal stem cell; EV: Extracellular vesicle; MSC-EV: Mesenchymal stem cell derived extracellular vesicle; MMP: Matrix metalloproteinase; VEGF: Vascular endothelial growth factor; TGFBR II: Transforming growth factor beta receptor II; SHIP-1: Src homology 2-containing inositol phosphatase-1; PD-1: Programmed death-1; PD-L1: PD-1 ligand; LCN2: Neutrophil gelatinase-associated lipocalin; APMAP: Adipocyte plasma membrane-associated protein.

Activity of T cells, and up-regulate IL-4, IL-10, and transforming growth factor-β and down-regulate IL-17 and interferon-γ in streptozotocin induced type-1 diabetes mellitus mice, thus deadening the progression of diseases[42]. MSCs have been extensively reported to decorate the activation of CD4+ T cells by some specific T cell effector cytokines or direct contact, down-regulating their immune activity and converting them to a regulatory phenotype (Treg)[43-44]. Programmed death-1 (PD-1) is a valuable cytokine inducing T cell activity. Research shows that MSCs express and secrete PD-1 ligands (PD-L1 and PD-L2) to regulate T cell dependent immune responses by binding with PD-1[45], suggesting that MSCs possess immunosuppressive properties via the modulation of T cells. AMSCs under stimulation with IFN-γ can secrete a big body of exosomes to the conditioned medium, and importantly, T cells isolated from that medium are significantly inhibited in activity and proliferation[46]. In a word, MSC-EVs down-regulate the activity and proliferation of T cells to inhibit T-dependent autoimmune responses.
**Table 2 Therapeutic potential of extracellular vesicles**

<table>
<thead>
<tr>
<th>Disease</th>
<th>EVs</th>
<th>Experimental sample</th>
<th>Therapeutic potential</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>MSC derived exosomal miR-150-5p</td>
<td>Collagen induced arthritis mouse model</td>
<td>MiR-150-5p could reduce joint destruction by inhibiting synoviocyte hyperplasia and angiogenesis</td>
<td>Chen et al. [80]</td>
</tr>
<tr>
<td></td>
<td>Exosome-encapsulated miR-548a-3p</td>
<td>Macrophage-like cells</td>
<td>MiR-548a-3p could inhibit the proliferation and activation of pTHP-1 cells via the TLR4/NF-κB signaling pathway</td>
<td>Wang et al. [81]</td>
</tr>
<tr>
<td></td>
<td>Exosome-encapsulated miR-6089</td>
<td>Macrophage-like cells</td>
<td>MiR-6089 could regulate LPS/TLR4-mediated inflammatory response</td>
<td>Xu et al. [82]</td>
</tr>
<tr>
<td></td>
<td>Exosome-derived IncRNA Hotair</td>
<td>Blood mononuclear cells</td>
<td>Hotair may contribute to the dissolution of bone and cartilage matrix through activation of MMP-2 and MMP-13 in osteoclasts and RA synoviocytes. Hotair is more stable and easily detected in body fluid</td>
<td>Song et al. [83]</td>
</tr>
<tr>
<td></td>
<td>Exosomal miR-17</td>
<td>Blood mononuclear cells</td>
<td>MiR-17 can suppress regulatory T cell differentiation by inhibiting the expression of TGFBR II</td>
<td>Wang et al. [84]</td>
</tr>
<tr>
<td></td>
<td>MicroRNA-155</td>
<td>MiR-155-deficient mice</td>
<td>MiR-155-deficient mice are resistant to collagen-induced arthritis, and antigen-specific Th17 cell and autoantibody responses are suppressed markedly to reduce articular inflammation</td>
<td>Kurowska-Stolarska et al. [85]</td>
</tr>
<tr>
<td></td>
<td>MicroRNA-146</td>
<td>Human RA synovial fibroblasts</td>
<td>MiR-146a is expressed in the superficial and sublining layers of synovial tissue, like synovial fibroblasts, macrophages, T cells, and B cells</td>
<td>Nakasa et al. [86]</td>
</tr>
<tr>
<td>SLE</td>
<td>Exosomal miR-26a</td>
<td>Female B6.MRLc1 and C57BL/6 mice; C57BL/6 (9 mo of age)</td>
<td>Podocytes mainly express miR-26a in mouse kidneys. Glomerular miR-26a expression in B6.MRLc1 mice correlates negatively with the urinary albumin levels and podocyte specific gene expression</td>
<td>Ichii et al. [87]</td>
</tr>
<tr>
<td>pSS</td>
<td>Exosomal miRNA-146a</td>
<td>Urine sample of SLE patients</td>
<td>Up-regulated exosomal miRNA-146a is found in the presence of active lupus nephritis</td>
<td>Perez-Hernandez et al. [88]</td>
</tr>
<tr>
<td></td>
<td>EV derived LCN2</td>
<td>Saliva and tear samples from pSS patients and healthy controls</td>
<td>EV derived LCN2 is over-expressed in pSS patients</td>
<td>Aqrawi et al. [89]</td>
</tr>
<tr>
<td></td>
<td>EV derived APMAP</td>
<td>Saliva and tear samples from pSS patients and healthy controls</td>
<td>EV derived APMAP is over-expressed in pSS patients</td>
<td>Aqrawi et al. [89]</td>
</tr>
<tr>
<td></td>
<td>EV derived CPNE1</td>
<td>Saliva and tear samples from pSS patients and healthy controls</td>
<td>EV derived CPNE1 is over-expressed in pSS patients</td>
<td>Aqrawi et al. [89]</td>
</tr>
<tr>
<td>IBD</td>
<td>MSC-EVs</td>
<td>LPS treated macrophages and an in vivo DSS induced mouse model</td>
<td>EVs promote the up-regulation of pro-inflammatory factors (TNF-α, IL-6, and IL-12) and down-regulation of the anti-inflammatory factor IL-10 in LPS-induced macrophages. EVs promote polarization of M1-like macrophages to an M2-like state</td>
<td>Cao et al. [90]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Exosomal PD-L1</td>
<td>MDA-MB-231 (251) human breast cancer cells and 4T1 mouse mammary tumor cells with PD-L1 expression or PD-L1KO</td>
<td>Exosomal PD-L1 binds to PD-1 on T cells to inhibit T cell activation and killing activities</td>
<td>Yang et al. [91]</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>EV derived miR-103a</td>
<td>Human adenocarcinoma cell lines NCI-H1437, NCI-H1792, and NCI-H2087 and human embryonic kidney HEK293 cells</td>
<td>miRNA inhibitor could inhibit effectively miR-103a mediated M2-type polarization, improving the cytokine profile of tumor infiltration macrophages</td>
<td>Hsu et al. [92]</td>
</tr>
</tbody>
</table>
**MSC-EVs and B lymphocytes**

B lymphocytes are also vital immune cells in adaptive immunity. A growing number of studies suggest that MSCs possess an immunomodulatory effect on B cells, but the molecular mechanisms involved are still mysterious\(^\text{[47]}\). Nevertheless, there is little research on the role of MSC-EVs in mediating the regulatory effect of B cells on inflammatory and immune responses. Membrane vesicles derived from MSCs inhibit both B cell proliferation and differentiation in a dose-dependent fashion\(^\text{[48]}\). Traggiai E and his colleagues found that MSCs positively influence the proliferation and differentiation of B cells into plasma cells secreting more immunoglobulins\(^\text{[47]}\). Thus, MSCs promote downstream immune responses by mediating the conversion of B cells. Systemic lupus erythematosus (SLE) is a typical autoimmune disease characterized by constantly producing various antibodies to counter autologous cells. It is well established that B cells play a critical role in autoimmune responses via autoantibodies dependent mechanisms. Therefore, we infer that MSCs mediated cell conversion can boost the inflammatory progression. Therefore, MSCs can serve as a potential therapeutic tool in autoimmune diseases.

**MSC-EVs and monocytes**

Monocytes are secreted from bone marrow into the circulatory system and transported to target tissue, where they differentiate into mature macrophages\(^\text{[49]}\). Macrophages are critical effectors and regulators of the immune system and play a central role in inflammation\(^\text{[50]}\). It has been well documented that macrophages can be divided into two subpopulations: The classic M1 and the alternative M2 macrophages under microenvironmental factors. The classical M1 macrophages are induced by TLR ligands and IFN-γ and alternative M2 macrophages are induced by the immune complex IL-4/IL-13\(^\text{[51-52]}\). M1 macrophages are characterized by strong microbicidal and tumoricidal activity, which can promote Th1 related inflammatory responses by releasing a range of proinflammatory cytokines, such as IL-6, IL-12, and TNF-α\(^\text{[53]}\), whereas M2 macrophages with anti-inflammatory function produce less proinflammatory cytokines and more IL-10 and other anti-inflammatory factors\(^\text{[54]}\). In short, both M1 and M2 macrophages contribute to the balance between destruction and repair of tissue in pathological conditions. A study suggested that after coculture...
Mesenchymal stem cell derived extracellular vesicles (MSC-EVs) exert immunomodulatory effect on innate and adaptive immune reactions mediated by many immune cells, primarily including T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages. In brief, MSC-EVs can inhibit the proliferation, differentiation, and activation of T, B, and natural killer cells and the pathogen-presenting function of dendritic cells and macrophages. In addition, macrophage polarization can be shifted under different microenvironments in accompany with MSC-EVs.

AMSCs with inflammatory cytokines IFN-γ and TNF-α, a higher level of exosomes can be detected in the medium supernatant, which induce M1 differentiate to anti-inflammatory M2 phenotype\(^5\). Adipose tissue accumulating constantly in the body leads to obesity and inflammatory responses, which increase the risk of incidence of many chronic diseases, including type 2 diabetes, cardiovascular events, and part of cancers\(^56\,57\,58\). Previous studies have revealed that the invasion of macrophages and T cells promote the formation of chronic inflammation in white adipose tissues\(^59\,60\). In high fat diet fed mice, AMSC derived exosomes promote white adipose tissue hypertrophy by inducing M2 macrophage polarization\(^61\). A study by Németh et al\(^62\) showed that endotoxin stimulated MSCs induce M2 macrophage polarization to release IL-10 and attenuate sepsis via the NF-κB signal pathway in a mouse model\(^62\). MSC-EVs induce the production of M2 macrophages with anti-inflammatory properties to restrain many relevant immune responses.

MSC-EVs and NK cells

NK cells, a vital cell type in the innate immune system, mediate cytotoxic activity and produce certain cytokines and chemokines to mediate antigen presentation, antiviral responses, autoimmune responses, and the occurrence of various autoimmune diseases\(^63\). A previous result showed that MSC-EVs injected into pericellular tissue depress the transfer of CD161\(^+\) NK cells, delay the progression of disease, and restore damaged tissue in autoimmune uveitis rat models\(^64\,65\). Decidua parietalis MSCs release IL-2 to CD69 (NK cell receptor) to stimulate IL-2 dependent NK cells and thus promote the proliferation of activated NK cells\(^66\). Decidua parietalis MSCs induce directly the activity of NK cells through IL-2 and CD69. Recent research suggested that fetal liver MSC derived exosomes carrying LAP, TGFβ, and TSP1 restrain the proliferation and activation of NK cells via TGFβ/Smad2/3 signaling\(^67\). Although available data show that MSC-EVs depress the activation and proliferation of NK cells, the research on that is limited in quantity and more studies need to be carried out in the future.

MSC-EVs and DCs

DCs, important bone marrow derived APCs, present multiple antigenic peptides (major histocompatibility complex - peptide complexes) to other immune cells, like T cells, and play a key role in bridging innate to adaptive immune systems. Coculture of
DCs with MSC-EVs led to down-regulated cellular surfactants and IL-10, IL-6, and IL-17 and up-regulated the number of regulatory T cells\(^{[84]}\), and the activity and maturation of DCs are apparently restrained. Many studies suggest that these MSC-EVs stimulate immature DCs to release TGF-β and PGE2, and regulate the immunocompetence of T cells in DC and T cell culture medium. Those small molecules mediate autoimmune responses with unclear mechanism. MSCs induce mature DCs to immature status with low immunogenicity and immunoregulatory property. The immature DCs express less immunomodulatory factors Ia, CD11c, CD80, CD86, and CD40, except for increased CD11\(^{[85]}\). Overall, MSC-EVs down-regulate the immune activity of DCs and T cell dependent adaptive immune responses indirectly. Nevertheless, the research on the interaction between DCs and MSC-EVs is limited, and the exact molecular mechanisms warrant further studies.

**MSC-EVs and autoimmune disease**

MSC-EVs have been suggested in many kinds of diseases, which can serve as promising strategies for autoimmune disease diagnosis and treatment, such as rheumatoid arthritis (RA), SLE, primary Sjögren’s syndrome (pSS), systemic sclerosis, and inflammatory bowel diseases (IBD) due to their vital role in intercellular communications. Nevertheless, the precise molecular mechanism underlying EV regulation in autoimmunity warrants in-depth investigation.

Epidemiological survey and analysis suggest that the incidence of autoimmune diseases has been increasing year by year over the past several decades\(^{[86]}\). Autoimmune diseases usually influence multiple organs and systems, such as the motor system, respiratory system, digestive system, and circulatory system\(^{[87]}\). They lead to a heavy burden to public health. It is well known that some autoimmune diseases are genetically susceptible\(^{[88]}\). Women tend to be affected by some autoimmune diseases, and approximately 90% of patients with autoimmune disease are female\(^{[89]}\). Currently, glucocorticoids and immunosuppressive drugs are still the most frequently used non-specific therapeutic agents. That traditional therapeutic strategy causes many adverse reactions, such as opportunistic infections and metabolic abnormalities, and the development of biological molecular targeted drugs to cause slower disease progression is a priority. Accumulating data reveal the biological features of MSCs in relieving immune cell-driven systemic inflammatory responses to down-regulate immune responses, such as autoimmune diseases\(^{[90]}\), and MSC-EVs are a significant regulator\(^{[91]}\). The current knowledge of EVs in autoimmune diseases will be discussed in detail in the following text.

**MSC-EVs and RA**

RA is one of the most common chronic and systemic autoimmune diseases involving multiple systems, which is characterized by the destruction of synovial joints. The representative clinical manifestations are redness, swelling, and pain of distal joints, especially small joints of hands and feet\(^{[92]}\). Many researchers have suggested that the occurrence of RA is caused by many complex factors, such as genetic factors and environmental factors\(^{[93]}\). Dysregulation of immune responses occupies a necessary position in RA.

Increasing data have revealed EVs as critical regulators in the pathogenesis of RA by delivering specific functional molecules to targeted cells. Previously, the effectiveness of MSC therapies has been elucidated in cartilage repair in both animal studies\(^{[94]}\) and human clinical trials\(^{[95]}\). Previous studies have revealed that EVs generated by MSCs play a critical role in protecting against cartilage destruction and enhancing cartilage regeneration. Particularly, exosomal noncoding RNAs (ncRNAs), including miRNAs and lncRNAs, have been implicated in regulating inflammation and immune response. MSC derived exosomal miR-150-5p down-regulated inflammatory responses and reduced joint destruction and vasculitis by targeting matrix metalloproteinase 14 (MMP14) and vascular endothelial growth factor in a collagen-induced arthritis mouse model, which is considered as a potential therapeutic biomarker for RA\(^{[96]}\). We have previously demonstrated the important role of exosome-encapsulated miR-6089 and miR-548a-3p in affecting macrophage-mediated inflammatory response in RA\(^{[97],\[98]}\). Exosome-derived lncRNA Hotair affected the migration of activated macrophages and significantly decreased the levels of MMP-2 and MMP-13, suggesting that it is a potential biomarker for RA\(^{[99]}\). A study by Wang et al\(^{[100]}\) has shown that exosomal miR-17 inhibits regulatory T cells by targeting TGFBR II in RA\(^{[101]}\). Besides, exosomes-encapsulated miR-155 and miR-146a produced by DCs can serve as important regulators in immune response and inflammatory response in RA\(^{[102]-[104]}\). It has been shown that the expression of exosomal amyloid A is positively correlated with anti-CCP antibody and CRP, suggesting a vital role of exosomal
protein in predicing the disease activity of RA patients\textsuperscript{[94]}. Taken together, exosomal ncRNAs play critical roles in regulating immune and inflammatory cells and thus participate in the occurrence and development of RA. Nevertheless, more studies are warranted to explore the molecular mechanisms of those exosomes harboring ncRNAs in the pathogenesis of RA.

**MSC-EVs and SLE**

SLE is a systemic autoimmune disease with various autoantibodies, which usually affects multi-organ systems due to enhanced inflammation and complex autoimmune disorders\textsuperscript{[95-97,108]}. It has been well established that SLE is caused by the abundant activation of T and B lymphocytes, elevated pro-inflammatory cytokines, sedimentation of immune complex substance, and finally multiple organ damage, while the kidney is the most commonly involved organ in SLE and lupus nephritis (LN) is often caused\textsuperscript{[98]}. EVs are significant regulators in mediating cell-to-cell communications involved in inflammation and immune regulations. Mounting evidence has suggested that EV delivered nucleic acids, proteins, autoantigens, cytokines, and surface receptors can serve as significant regulators in SLE\textsuperscript{[97,98,108-111]}. Microvesicles purified from SLE patients have been identified to contain higher concentrations of immunoglobulins and complement\textsuperscript{[97,108,112]}. Circulating exosomes from patients with SLE have been shown to induce a proinflammatory immune response, which is characterized by high levels of TNF-α, IL-1β, IL-6, and other inflammatory mediators\textsuperscript{[97,108,112]}. The study by Asami \textit{et al}\textsuperscript{[101]} supports that MSCs may confer immunosuppressive effects in SLE\textsuperscript{[97,108,112,113]}. Previously published studies have elucidated that the EVs produced from MSCs, can also contribute to immunosuppressive function in SLE\textsuperscript{[97,107,108]}. Accordingly, EVs can be used as drug carriers because they are less immunogenic. Umbilical cord derived MSCs have been used in the treatment of SLE patients, which shows good tolerance and few adverse events associated with transplantation\textsuperscript{[97,107,108,112]}. Therefore, MSCs and MSC-EVs can effectively control the active SLE and be used as a therapeutic strategy, particularly for the treatment of refractory SLE. Ichii and the colleagues have found that exosomal miR-26a is positively associated with urinary protein level, which suggests that exosomal miR-26a in urine of LN patients can be used as a potential biomarker for predicting podocyte injury\textsuperscript{[101]}.

In addition, Perez-Hernandez \textit{et al}\textsuperscript{[99]} have shown that urinary exosomal miRNA-146a is significantly up-regulated in active LN patients\textsuperscript{[100]}. Therefore, testing urinary exosomal miRNA can be a non-invasive method for the detection and monitoring of LN. Nevertheless, the specific molecular mechanism of EVs in regulating autoimmunity in SLE is still unclear, which warrants further investigation by more future studies.

**MSC-EVs and pSS**

pSS is a systemic autoimmune disease that is characterized by chronic lymphocyte infiltration in the exocrine glands, primarily the lacrimal and salivary glands\textsuperscript{[91,92,107]}. The primary target organs are the lacrimal and salivary glands, and dry eyes and dry mouth are often caused\textsuperscript{[92,107]}. EVs purified from saliva\textsuperscript{[91,92,107]} and tear fluid\textsuperscript{[91,92,107]} have been identified to be potential biomarkers for the diagnosis and treatment of pSS in previous studies. Those differentially expressed proteins isolated from EVs of saliva and tear fluid from patients with pSS can contribute to pSS by regulating TNF-α signaling and B cell survival, including neutrophil gelatinase-associated lipocalin, adipocyte plasma membrane-associated protein, and copine\textsuperscript{[107]}\textsuperscript{[93]}. The increase of platelet-derived microvesicles, soluble CD40 ligand (sCD40L), and soluble P-selectin (sCD62P) in pSS patients reflects platelet activation, which can serve as disease biomarkers\textsuperscript{[94,105]}. Currently, studies on MSC-EV mediated immune responses in pSS are rare. More studies are needed to elucidate the role and underlying mechanisms of EVs in pSS.

**MSC-EVs and IBD**

IBD is a common digestive disease characterized by chronic, relapsing gastrointestinal tract inflammatory reactions, including two main forms, Crohn’s disease and ulcerative colitis\textsuperscript{[96,107]}. To the best of our knowledge, the pathogenic mechanisms and pathogenesis of IBD are complicated, and many factors contribute to the occurrence of this disease, like autoimmune disorder, genetics, and environment\textsuperscript{[111]}. Macrophages have been seen as important immune cells inducing IBD\textsuperscript{[112]}. Experimental studies showed that inflammatory responses are significantly restrained by inducing the production of M2 macrophages in the dextran sulphate sodium induced mouse model of colitis\textsuperscript{[113]}. Moreover, higher levels of immunosuppressive factors (IL-10 and TGF-β)
were observed in mice treated with MSC-EVs, promoting repair and regeneration of damaged epithelial cells[10]. Studies have confirmed that MSC-EVs down-regulate the production of IL-1β, NO, and IL-18 by depressing NF-κB and iNOS-driven signaling in 2,4,6-trinitrobenzene sulfonic acid induced colitis[11,12]. Therefore, MSC-EVs, as an important regulator, can suppress inflammatory responses and promote injured tissue repair. That delineates the potential of MSC-EVs as biomarkers for IBD treatment.

**MSC-EVs and tumor immunity**

Tumor immunity is critical in the processes of immune response, immune escape, and immune surveillance in cancer[13,14]. Previous research findings show that EVs play an critical role in anti-tumor immune reaction and inflammatory response during carcinogenesis and cancer progression[15]. In the last decade, exosomes have attracted more and more attention in cancer immunity, particularly as tumor suppressors[16]. Some bioactive factors encapsulated in EVs promote immune and inflammatory responses and thus lead to tumorigenesis, while some exert immune suppressive effects by inducing Tregs and M1 polarization.

A previous study has demonstrated the specific binding capacity of exosomal PD-L1 to its receptor PD-1 to depress the anti-tumor effect of T cells in breast cancer[17]. MSCs also express and release PD-L1 to regulate T cell activity, and thus both MSCs and exosomes possess immunosuppressive effect[18]. Besides, it has been documented that EVs play a critical role in anti-tumor immune response by regulating macrophages polarization. It has been found that EVs-delivering miR-103a contributes to lung cancer by targeting PTEN and inducing M2 polarization[19]. Similarly, exosomal miR-301a-3p purified from pancreatic cancer cells was found to induce M2 macrophage polarization via the PTEN/P13Kγ signaling pathway[20]. Taken together, EVs, particularly MSC-EVs, exert immunomodulatory effects on cancer and mediate intercellular communications between cancer cells and immune cells through EVs harboring bioactive molecules, including proteins and ncRNAs.

**MSC-EVs and transplantation immunity**

Kidney transplantation is the current preferred treatment for end stage renal disease. However, the long-term survival rate of the transplanted kidney is still low because the transplanted recipients often suffer from acute or chronic rejection for a long period of time[21], which finally leads to graft-versus-host disease. Biopsy is still the gold standard for the diagnosis of rejection of kidney transplantation[22,23], but it is risky and traumatic. EVs in urine can be a potential biomarker for monitoring kidney transplant rejection[24]. T cells infiltrate the renal tubule during acute inflammatory response, which is a major cause for transplanted renal damage. MSC-EVs possess potential of inhibition of T cell activity and proliferation and thus EVs tend to gather in damaged renal tissues and are more likely to enter the urine. Consequently, using urine for detecting rejection of kidney transplantation is more likely to operate and promising. In addition, a previous report has showed that MSC derived exosomes provide a novel and effective clinical treatment for graft-versus-host disease[25]. Nonetheless, the role of MSC-EVs in transplantation immunity needs to be further investigated in the future.

**Conclusions and prospects**

MSC-EVs are a hot topic in current molecular biology. Accumulated data have implicated their immunomodulatory effects on many immune cells, including T cells, B cells, macrophages, NK cells, and DCs. Increasing studies have confirmed that MSC-EVs can serve as regulators in the pathogenesis of autoimmune related diseases. In particular, MSC-EVs and the encapsulated bioactive molecules are potential targets for the diagnosis and treatment of autoimmune disease, cancer, and other diseases. MSC-EVs can serve as new medicines in the suppression of inflammatory responses. Increasing experimental results show that application of MSC-EVs can effectively inhibit immune reactions and promote the survival and regeneration of injured cells. However, there is still a long way for investigating the therapeutic strategy for autoimmune related diseases based on MSC-EVs. More in-depth research is warranted in the future, particularly regarding the molecular mechanism of MSC-EVs in autoimmunity.
ARTICLE HIGHLIGHTS

Research background
Mesenchymal stem cells (MSCs) have been reported to possess immune regulatory effects in innate and adaptive immune reactions. MSCs can mediate intercellular communications by releasing extracellular vesicles (EVs), which deliver functional molecules to targeted cells. MSC derived EVs (MSC-EVs) confer altering effects on many immune cells, including T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages. A large number of studies have suggested that MSC-EVs participate in regulating autoimmunity related diseases. This characteristic of MSC-EVs makes them be potential biomarkers for the diagnosis and treatment of autoimmunity related diseases.

Research motivation
This article describes and focuses on the identification, characteristics, immunomodulatory function, and underlying mechanism of MSC-EVs in autoimmunity related diseases. Understanding the immunomodulation effects of MSC-EVs better will help us to investigate the pathogenesis of diseases and develop novel targeted medicines.

Research objectives
The immune modulation of MSC-EVs play a key role in disease initiation, maintenance, and progression. This article provides a new direction for us to understand the precise mechanisms of action of autoimmunity related diseases, which will promote the improvement of therapeutic regimen.

Research methods
Literature search was conducted in PubMed to retrieve articles published between 2010 and 2020 in the English language. The keywords, such as “MSCs,” “EVs,” “autoimmune responses,” “immune cells,” and “autoimmunity related diseases,” and Boolean operator “AND” and “NOT” coalesced admirably to be used for searching in vitro studies on the specific molecular mechanisms of MSC-EVs in many immune cell types and many autoimmunity related diseases. Studies that did not investigate the molecular mechanisms of MSC-EVs in the occurrence and development of autoimmune diseases were excluded.

Research results
A large number of articles were retrieved and their abstracts were skimmed. When analyzing the publications, we found that it has been well documented that MSC-EVs have the ability to induce multiple immune cells, like T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages, to regulate immune responses in innate immunity and adaptive immunity. Many validated EVs-delivered molecules have been identified as key biomarkers, such as proteins, lipids, and nucleotides. Some EVs-encapsulated functional molecules can serve as promising therapeutic targets particularly for autoimmune disease.

Research conclusions
MSC-EVs play an important part in the differentiation, activation, and proliferation of immune cells, and they may become potential biomarkers for the diagnosis and treatment of autoimmunity related diseases.

Research perspectives
MSC-EVs can serve as regulators in the pathogenesis of autoimmune related diseases. In particular, MSC-EVs and the encapsulated bioactive molecules are potential targets for the diagnosis and treatment of autoimmune disease, cancer, and other diseases. However, there is still a long way for investigating the therapeutic strategy for autoimmunity related diseases based on MSC-EVs. More in-depth research is warranted in the future, particularly regarding the molecular mechanism of MSC-EVs in autoimmunity.
REFERENCES


9 Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20: 14-20 [PMID: 22008910 DOI: 10.1038/mmt.2011.211]


25 Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumour-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA 2009; 106:
MSC-EVs in autoimmunity


Immunological and therapeutic implications. Autoimmune disease and the environment.

Wang JH et al. MSC-EVs in autoimmunity
Wang JH et al. MSC-EVs in autoimmunity


Wang JH et al. MSC-EVs in autoimmunity


110 Hudson R. Inflammatory bowel disease. Nature 2016; 540: 879 [PMID: 28002398 DOI: 10.1038/s41587-017-00364-z]


121 Hsu YL, Hung JY, Chang WA, Jian SF, Lin YS, Pan YC, Wu CY, Kuo PL. Hypoxic Lung-Cancer-Derived Extracellular Vesicle MicroRNA-103A Increases the Oncogenic Effects of Macrophages by Targeting PTEN. Mol Ther 2018; 26: 588-581 [PMID: 29292163 DOI: 10.1038/s41397-017-0116e]


